Latuda (lurasidone)
MarketedSchizophrenia and bipolar-disorder drug that reached sixth place in its Korean prescription market two years after launch.
FROM PUBLIC EVENTS · 2026-11-15
Late clinical · capacity Has started a Phase 3 trial to widen the indications of its lead product Latuda.
Roles often seen at this stageClinical & PV · Sales & marketing · Regulatory affairs
A pharmaceutical company selling prescription drugs centred on the central nervous system, including Latuda for schizophrenia and bipolar disorder.
Schizophrenia and bipolar-disorder drug that reached sixth place in its Korean prescription market two years after launch.
Korean Phase 3 trial to add adjunctive treatment of major depressive disorder as an indication.
Received approval for a Phase 3 trial of Latuda as adjunctive treatment for major depressive disorder.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.